Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease

Table 1 Demographics and clinical characteristics

Characteristics	Control group (n = 43)	AD group (n = 43)	p Value
Sex, M/F, %	47/53	36/64
Age at examination, years^a	61 (43–80)	78 (60–94)	<0.001
MMSE score^a	29 (24–30)	18 (4–23)	< 0.001
APOE ε4 status (−/−, +/−, +/+)	33, 8, 2	12, 24, 7
CSF Aβ₄₂, pg/mL^a	539 (200–990)	335 (140–530)	< 0.001
CSF t-tau, pg/mL^a	323 (89–690)	700 (360–1990)	< 0.001
CSF p-tau, pg/mL^a	41 (20–87)	88 (44–226)	< 0.001

Abbreviations: AD Alzheimer’s disease, APOE Apolipoprotein E, Aβ₄₂ Amyloid-β 1–42, CSF Cerebrospinal fluid, MMSE Mini Mental State Examination, p-tau Phosphorylated tau, t-tau Total tau
Age at examination, MMSE scores, Aβ₄₂, t-tau and p-tau are presented as median with range
p Values reported are derived from non-parametric comparisons of each pair using Wilcoxon’s method. APOE ε4 genotype status is presented as null (−/−), heterozygous (+/−) and homozygous (+/+)
^aMedian (minimum–maximum)

ISSN: 1758-9193